New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
16:03 EDTSCLN, SNYSciClone announces product promotion agreement renewal with Sanofi in China
SciClone (SCLN) announced that it has successfully negotiated renewals of its exclusive product promotion agreement with Sanofi (SNY) for the China market. Under the terms of the Sanofi agreement, SciClone, through its wholly owned subsidiary, Novamed Pharmaceuticals, exclusively promotes four key products: the anti-epileptic Depakine; the hypnotic Stilnox; the ACE inhibitor Tritace and Xatral, an alpha-1 adrenergic blocker used to treat benign prostatic hyperplasia or BPH. Depakine revenues rank second among SciClone's revenue-generating products and during the last three years under the promotional agreement, sales have increased significantly on an annual compounded basis. As the set of current agreements will expire between the end of 2012 and June 30, Sanofi and Novamed have decided to group the products and renew their agreement till December 31, which may be further extended should both parties find agreement under the terms of the contract extension.
News For SCLN;SNY From The Last 14 Days
Check below for free stories on SCLN;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:33 EDTSNYMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
September 12, 2014
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
September 11, 2014
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
September 3, 2014
12:49 EDTSNYSanofi reports Dengue vaccine candidate achieves its phase 3 primary endpoint
Sanofi Pasteur, the vaccines division of Sanofi, announced that the final landmark phase 3 efficacy study of its dengue vaccine candidate in Latin America successfully achieved its primary clinical endpoint. Results showed an overall significant reduction of 60.8% of dengue disease cases in children and adolescents 9-16 years old after a three-dose vaccination schedule. Importantly, efficacy was observed against each of the four dengue serotypes. Additional observations of the results showed a clinically important reduction by 80.3% in the risk of hospitalization due to dengue during the study. The results also showed in the study population an efficacy against dengue haemorrhagic fever, the severe form of dengue, which is consistent with the results released from Sanofiís phase 3 dengue study in Asia. Lastly, the results suggest better protection in case of prior exposure to dengue.
September 2, 2014
20:26 EDTSNYSanofi has a conference call hosted by JPMorgan
Subscribe for More Information
13:58 EDTSNYRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
08:35 EDTSNYIntrexon enters into ECC with Sanofi subsidiary to develop APIs
Subscribe for More Information
07:21 EDTSNYRegeneron data positive, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use